Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Technische Universitat Darmstadt

Xixi Feng

Gerd Ruehter

Felix Hausch

Steffen Gaali

Alexander Kirschner

Andreas Bracher

The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

Selective FKBP51 ligands for treatment of psychiatric disorders

The present invention relates to compounds of the general formula (I) having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions. 

Growing community of inventors

Munich, Germany

Xixi Feng